Scarica l'app Stockscreener
26.88
5.52%
-1.57
Dopo l'orario di chiusura:
27.48
0.60
+2.23%
Precedente Chiudi:
$28.45
Aprire:
$27.7
Volume 24 ore:
835.84K
Relative Volume:
0.81
Capitalizzazione di mercato:
$3.69B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-8.29%
1M Prestazione:
+0.60%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$26.85
$29.75
Intervallo di 1 settimana:
$26.00
$29.75
Portata 52W:
$12.30
$37.99
Metsera Inc Stock (MTSR) Company Profile
Nome
Metsera Inc
Settore
Industria
Telefono
(212) 784-6595
Indirizzo
3 WORLD TRADE CENTER, NEW YORK
Confronta MTSR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
26.88 | 3.69B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-25 | Iniziato | BofA Securities | Buy |
| 2025-02-25 | Iniziato | Evercore ISI | Outperform |
| 2025-02-25 | Iniziato | Guggenheim | Buy |
Metsera Inc Borsa (MTSR) Ultime notizie
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN
Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha
Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily
Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World
Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World
Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha
Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter
Metsera price target raised to $62 from $56 at Guggenheim - TipRanks
Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan
Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews
Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Metsera chasing best-in-class profile with amylin program - biocentury.com
Metsera reports promising Phase 1 trial results for obesity treatment By Investing.com - Investing.com South Africa
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - GlobeNewswire
Metsera’s Amylin Analog Stars In Obesity Phase I - insights.citeline.com
Obesity treatment startup Metsera rises on positive trial results - Sherwood News
metsera reports positive phase 1 trial results for obesity drug - Investing.com Australia
Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes By Stocktwits - Investing.com India
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial - MSN
Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga
Metsera obesity monotherapy data ‘looks competitive,’ says BofA - TipRanks
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - MSN
Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive
Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Benzinga
Metsera's Phase 1 Trial of MET-233i Shows Weight Reduction With no Severe Adverse Events - marketscreener.com
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks - BioSpace
Metsera’s drug shows potential in early clinical trial - statnews.com
metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com Canada
Metsera shares soar on positive amylin candidate trial results By Investing.com - Investing.com Nigeria
Metsera shares soar on positive amylin candidate trial results - Investing.com Australia
Metsera announces topline data from Phase 1 trial of MET-233i - TipRanks
Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results - Bloomberg.com
Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com
Metsera’s amylin drug shows early potential for substantial weight loss - statnews.com
Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® - The Manila Times
Metsera to Present New Research Highlighting the Breadth - GlobeNewswire
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association - TradingView
Next-Gen Monthly Obesity Drug Shows Promise: Metsera to Present Breakthrough Clinical Data at ADA 2025 - Stock Titan
Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com
Metsera Inc Azioni (MTSR) Dati Finanziari
Non sono disponibili dati finanziari per Metsera Inc (MTSR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Metsera Inc Azioni (MTSR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):